Intersect ENT Inc. will move from Palo Alto to new headquarters in Menlo Park, quadrupling its space as it commercializes its device to treat chronic sinusitis.
The 32,000-square-foot facility at 1555 Adams Drive will house all business and manufacturing operations for Propel, a stent that is placed in the sinus cavities right after sinus surgery. The device keeps the sinuses open and releases corticosteroid over a period of time before dissolving.
No comments:
Post a Comment